Understanding Heart Damage from Doxorubicin Chemotherapy
Role of oxidative stress in doxorubicin-induced cardiotoxicity
['FUNDING_OTHER'] · LOUISIANA STATE UNIV HSC SHREVEPORT · NIH-11143034
This research explores why some patients experience heart damage from doxorubicin chemotherapy while others don't, focusing on individual genetic differences.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | LOUISIANA STATE UNIV HSC SHREVEPORT (nih funded) |
| Locations | 1 site (SHREVEPORT, UNITED STATES) |
| Trial ID | NIH-11143034 on ClinicalTrials.gov |
What this research studies
Doxorubicin is a powerful chemotherapy drug, but it can sometimes harm the heart. We know that people react differently to this drug, and their genes play a big part in how severe any heart damage might be. This project looks into how a process called oxidative stress, which is also influenced by your genes, contributes to this heart damage. We are specifically interested in a newly identified genetic area that might control how much oxidative stress occurs in heart cells.
Who could benefit from this research
Good fit: Patients who have received doxorubicin chemotherapy or are considering it, especially those concerned about heart side effects, may find this research relevant.
Not a fit: Patients not receiving doxorubicin chemotherapy or those without concerns about its cardiac side effects may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could help doctors predict which patients are at higher risk for heart damage from doxorubicin and potentially lead to ways to prevent it.
How similar studies have performed: While the general link between doxorubicin and cardiotoxicity is known, this research explores a novel genetic locus and its role in oxidative stress, building on preliminary data.
Where this research is happening
SHREVEPORT, UNITED STATES
- LOUISIANA STATE UNIV HSC SHREVEPORT — SHREVEPORT, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MOHAMED, TAREK MAGDY — LOUISIANA STATE UNIV HSC SHREVEPORT
- Study coordinator: MOHAMED, TAREK MAGDY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.